Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P160045/S049

Oncomine Dx Target Test

Life Technologies Corporation · Decision date Aug 8, 2025

FDA DECISIONP160045/S049

What did the FDA approve?

FDA records P160045/S049 as a supplement to PMA P160045, with the supplement type “Normal 180 Day Track”. The recorded decision is approval, dated Aug 8, 2025.

FDA approval order statement

Approval to include a companion diagnostic indication to identify patients with non-small cell lung cancer (NSCLC) harboring ERBB2/HER2 activating mutations in the tyrosine kinase domain (SNVs in exons 18-21 and exon 20 insertions) who are eligible for treatment with HERNEXEOS (zongertinib).
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track
Clinical specialty
Pathology
Decision date
Aug 8, 2025
FDA change category
Labeling Change - Indications/instructions/shelf life/tradename

FDA source record

Regulatory record facts

Identifier
P160045/S049
Regulatory pathway
PMA supplement
Product code
PQP
Decision code
APPR
Decision date
Aug 8, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Next generation sequencing oncology panel, somatic or germline variant detection system.

Product code
PQP
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P160045/S049 received

    Application receipt date recorded by FDA.

  2. P160045/S049 · FDA decision

    Normal 180 Day Track

  3. P160045/S050 · Related supplement

    Oncomine Dx Target Test

  4. P160045/S051 · Related supplement

    Oncomine Dx Target Test

  5. P160045/S052 · Related supplement

    Oncomine Dx Target Test

Timeline entries are records held by MedtechLedger for P160045. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P160045

Product / regulatory recordCompanyPathwayDecision dateSource
Life Technologies CorporationPMA supplementNov 19, 2025FDA
Life Technologies CorporationPMA supplementNov 21, 2025FDA
Life Technologies CorporationPMA supplementMar 4, 2026FDA

Explore the linked device profile

Other records with product code PQP

Product / regulatory recordCompanyPathwayDecision dateSource
Life Technologies CorporationPMA supplementNov 4, 2026FDA
xT CDxP210011/S006
Tempus AI, Inc.PMA supplementOct 23, 2026FDA
MI Cancer SeekP240010/S007
Caris Life SciencesPMA supplementOct 16, 2026FDA
Foundation Medicine, Inc.PMA supplementSep 18, 2026FDA
Guardant360 CDxP200010/S029
Guardant Health, Inc.PMA supplementSep 18, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Life Technologies Corporation

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
5781 Van Allen Way, Carlsbad, CA, 92008

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records